Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Informe acción SEHK:2315
Capitalización de mercado: HK$2.3b
Biocytogen Pharmaceuticals (Beijing) Dividendos y recompras
Dividendo controles de criterios 0/6 Biocytogen Pharmaceuticals (Beijing) no tiene historial de pago de dividendo.
Información clave
n/a
Rentabilidad por dividendo
-0.004%
Rendimiento de la recompra
Rendimiento total para el accionista -0.004% Rendimiento futuro de los dividendos 0% Crecimiento de los dividendos n/a Próxima fecha de pago de dividendos n/a Fecha ex dividendo n/a Dividendo por acción n/a Ratio de pago n/a
Últimas actualizaciones de dividendos y recompras
Mostrar todas las actualizaciones
First half 2024 earnings released: CN¥0.13 loss per share (vs CN¥0.48 loss in 1H 2023) Sep 28
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. to Report Q2, 2024 Results on Aug 28, 2024 Aug 16
Is Biocytogen Pharmaceuticals (Beijing) (HKG:2315) A Risky Investment? May 08
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s (HKG:2315) Price Is Right But Growth Is Lacking Apr 03
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Annual General Meeting, May 28, 2024 Mar 29
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Annual General Meeting, May 28, 2024 Mar 28
Full year 2023 earnings released: CN¥0.96 loss per share (vs CN¥1.58 loss in FY 2022) Mar 28
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. to Report Fiscal Year 2023 Results on Mar 27, 2024 Mar 16
New minor risk - Share price stability Feb 16
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Approves Election of Ms. Li Yan as A Non-Employee Representatives Supervisor of the Company Dec 13
New minor risk - Share price stability Oct 06
Biocytogen Pharmaceuticals' RenMice Series-Fully Human Antibody and TCR Mouse Models-Showcase Biocytogen's Capabilities to Innovate the Discovery of Biologic Drugs Sep 15
Forecast to breakeven in 2025 Aug 31
First half 2023 earnings released: CN¥0.48 loss per share (vs CN¥0.73 loss in 1H 2022) Aug 30
New minor risk - Profitability Aug 29
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Announces Project Integrum Achieves Milestone Progress, Accelerating Antibody Business Growth Aug 18
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. to Report First Half, 2023 Results on Aug 28, 2023 Aug 16
Forecast to breakeven in 2025 Mar 29
Full year 2022 earnings: EPS and revenues miss analyst expectations Mar 28
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Launches Rennano Mouse, Fully Human Heavy Chain Antibody Platform to Accelerate Nanobody Drug Discovery Dec 30
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Announces FDA Clearance of IND Application for Bispecific Antibody YH008 Dec 19
Less than half of directors are independent Nov 16
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Announces Management Appointments Nov 08
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Announces Resignation of Huang Xiaolu as Non-Executive Director and A Member of the Strategy Development Committee Oct 18
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. to Present at Biojapan2022, Introducing Innovative R&D Platforms, Bispecific ADC Programs and Pipeline Progress Sep 28
First half 2022 earnings released: EPS: CN¥0 (vs CN¥0 in 1H 2021) Sep 27
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has completed an IPO in the amount of HKD 548.74937 million. Sep 01
Less than half of directors are independent Sep 01
Estabilidad y crecimiento de los pagos
Obteniendo datos sobre dividendos
Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de 2315 han sido estables en el pasado.
Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de 2315 han aumentado.
Rentabilidad por dividendo vs. Mercado Rentabilidad por dividendo de Biocytogen Pharmaceuticals (Beijing) vs. Mercado
¿Cómo se compara la rentabilidad por dividendo de 2315 con la del mercado? Segmento Rentabilidad por dividendo Empresa (2315) n/a Suelo de mercado 25% (HK) 3.2% Techo de mercado 25% (HK) 8.0% Media de la industria (Biotechs) 1.1% Analista de previsiones (2315) (hasta 3 años) 0%
Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de 2315 en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.
Alto dividendo: No es posible evaluar la rentabilidad por dividendo de 2315 en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.
Pago de beneficios a los accionistas
Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de 2315 para determinar si sus pagos de dividendos están cubiertos por los beneficios.
Pago en efectivo a los accionistas
Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que 2315 no ha comunicado ningún pago.
Descubre empresas que pagan buenos dividendos Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
